MedTrace Logo

Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

NCT02736474 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.

Conditions

Interventions

DRUG

Naltrexone

3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.

DRUG

Placebo Naltrexone

Placebo Naltrexone created and masked by the pharmacy to be used as a control.

DRUG

Bupropion

1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.

DRUG

Placebo Bupropion

Placebo Bupropion created and masked by the pharmacy to be used as a control.

Sponsors & Collaborators

  • University of Massachusetts, Worcester

    collaborator OTHER

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Jiang Du, PhD · Chief Physician

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-07-31
Completion
2018-07-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02736474 on ClinicalTrials.gov